3.05

2.24% -0.07

Altimmune Inc (ALT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

$3.12

Aprire:

$3.12

Volume 24 ore:

2.99M

Relative Volume:

0.71

Capitalizzazione di mercato:

$593.15M

Reddito:

$36,000

Utile/perdita netta:

$-91.08M

Rapporto P/E:

-3.253

EPS:

-0.9376

Flusso di cassa netto:

$-71.67M

1 W Prestazione:

-3.48%

1M Prestazione:

+16.86%

6M Prestazione:

-24.13%

1 anno Prestazione:

-30.68%

Intervallo 1D:

$2.95

$3.135

Intervallo di 1 settimana:

$2.93

$3.30

Portata 52W:

$2.56

$6.4399

Altimmune Inc Stock (ALT) Company Profile

Nome

Altimmune Inc

Settore

Healthcare (1096)

Industria

Biotechnology (616)

Telefono

(240) 654-1450

Indirizzo

910 CLOPPER ROAD, GAITHERSBURG, MD

Dipendente

Cinguettio

Prossima data di guadagno

2026-08-11

Ultimi documenti SEC

ALT's Discussions on Twitter

Compare ALT vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ALT Altimmune Inc	3.05	593.15M	36,000	-91.08M	-71.67M	-0.9376
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Altimmune Inc Stock (ALT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-04-24	Aggiornamento	Goldman	Sell → Neutral
2026-03-18	Iniziato	Truist	Buy
2026-01-28	Iniziato	Barclays	Overweight
2025-07-10	Ripresa	Goldman	Sell
2025-02-28	Iniziato	William Blair	Mkt Perform
2025-01-08	Iniziato	Stifel	Buy
2024-11-12	Iniziato	UBS	Buy
2024-04-29	Downgrade	Guggenheim	Buy → Neutral
2024-01-24	Iniziato	Goldman	Neutral
2023-03-22	Downgrade	Goldman	Buy → Neutral
2022-12-01	Iniziato	Goldman	Buy
2021-12-29	Ripresa	Jefferies	Buy
2021-06-02	Iniziato	H.C. Wainwright	Buy
2021-02-11	Iniziato	Guggenheim	Buy
2020-12-14	Iniziato	Jefferies	Buy
2020-11-12	Reiterato	B. Riley Securities	Buy
2020-09-25	Iniziato	B. Riley FBR	Buy
2020-08-14	Iniziato	Evercore ISI	Outperform
2020-07-31	Iniziato	Piper Sandler	Overweight
2020-07-28	Iniziato	JMP Securities	Mkt Outperform
2020-02-24	Ripresa	ROTH Capital	Buy
2019-07-19	Iniziato	ROTH Capital	Buy
2017-10-09	Iniziato	Piper Jaffray	Overweight

Mostra tutto

Altimmune Inc Borsa (ALT) Ultime notizie

Jul 09, 2026

Altimmune advances research to address alcohol use disorder and liver disease link - Traders Union

Jul 09, 2026

LULU, LCID, ALT Stocks Hit 52-Week Lows Today: What's Driving The Selloff? - Stocktwits

Jul 09, 2026

Altimmune, Inc. Actuals & Estimates (DUS:3G0) - TradingView

Jul 09, 2026

Jul 07, 2026

Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing CatalystUpgrade (ALT) - Seeking Alpha

Jul 07, 2026

Here's why you should add Altimmune stock to your portfolio now - MSN

Jul 07, 2026

Jul 05, 2026

Leerink Sees Altimmune (ALT) As An Attractive Play In The MASH Therapeutics Market - Yahoo Finance

Jul 05, 2026

Jul 04, 2026

5 Overlooked Penny Stocks to Buy Right Now - Insider Monkey

Jul 04, 2026

ETFs Investing in Altimmune, Inc. Stocks - TradingView

Jul 04, 2026

Jun 30, 2026

ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside? - Stocktwits

Jun 30, 2026

ALT Stock Drops Pre-Market On Dilution Fears – Retail Calls It A ‘Horror Story’ - Stocktwits

Jun 30, 2026

Medicare Obesity Drug Coverage Puts These 3 Biotech Stocks In Focus - Sahm

Jun 30, 2026

Jun 29, 2026

VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits

Jun 29, 2026

Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026

Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026

Altimmune, Inc.(NasdaqGM: ALT) added to Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026

Altimmune, Inc.(NasdaqGM: ALT) added to Russell Microcap Value Benchmark Index - marketscreener.com

Jun 29, 2026

Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026

ALT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce - The National Law Review

Jun 29, 2026

Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

ALT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Annou - The National Law Review

Jun 28, 2026

ALT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Annou - The National Law Review

Jun 28, 2026

Altimmune, Inc.(NasdaqGM: ALT) added to Russell 2500 Value Benchmark - marketscreener.com

Jun 28, 2026

Jun 27, 2026

ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns - Stocktwits

Jun 27, 2026

Price to book forward of Altimmune, Inc. – NASDAQ:ALT - TradingView

Jun 27, 2026

Price to book forward of Altimmune, Inc. – SWB:3G0 - TradingView

Jun 27, 2026

Enterprise value to revenue forward of Altimmune, Inc. – NASDAQ:ALT - TradingView

Jun 27, 2026

Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker - The Globe and Mail

Jun 26, 2026

Price to earnings forward of Altimmune, Inc. – BMV:ALT1 - TradingView

Jun 26, 2026

Price to sales forward of Altimmune, Inc. – BMV:ALT1 - TradingView

Jun 26, 2026

Altimmune, Inc. Actuals & Estimates (NASDAQ:ALT) - TradingView

Jun 26, 2026

Enterprise value to EBIT forward of Altimmune, Inc. – NASDAQ:ALT - TradingView

Jun 26, 2026

Enterprise value to EBIT forward of Altimmune, Inc. – BMV:ALT1 - TradingView

Jun 26, 2026

Jun 25, 2026

Enterprise value to EBITDA forward of Altimmune, Inc. – NASDAQ:ALT - TradingView

Jun 25, 2026

ALT stock guide to pemvidutide's MASH, AUD and ALD setup - MSN

Jun 25, 2026

ALT Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

A2N5Z6 Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 24, 2026

Is Altimmune, Inc. (ALT) Still a Buy After Price Target Reduction to $20? - Insider Monkey

Jun 24, 2026

Is Altimmune worth buying ahead of 2026 catalysts? - MSN

Jun 24, 2026

Jun 23, 2026